Redeye returns with an updated view on Lifecare following its year-end report, which warranted some adjustments to 2025/2026 estimates.
Redeye updates its view on Lifecare following its Q3 report.
Redeye comments on Lifecare following today’s news that the company has completed a key development phase and submitted a phase-end report t...
Redeye comments on Lifecare, following the company's advancements in automating production at its facilities in Mainz, Germany, and the anno...
Redeye has updated its fair value range for Lifecare following the company's reverse share split, a process carried through to prepare the c...
Redeye updates its view on Lifecare following the Q2 report and recent company developments, including confirmed sensor longevity of nine we...
Redeye comments on Lifecare after the announcement that its rights issue was oversubscribed, reinforcing its balance sheet with NOK90m in gr...
Redeye sees a positive press release from Lifecare confirming that the company has managed to improve the read-out distance to start the pen...
Redeye updates its outlook and fair value range on Lifecare following the company’s Q1 report and announced capital raise.
Redeye leaves its initial comments on Lifecare following the announcement of raising NOK75-95m in gross proceeds through a guaranteed rights...
Redeye views today's press release from Lifecare positively, announcing that it has reached the target for pilot production of the Sencell s...
Redeye makes minor upwards adjustments to its fair value range following Lifecare’s year-end report 2023.
Redeye leaves its initial take on Lifecare's year-end report that came in higher than anticipated on revenues but lower on EBIT.
Redeye expects an eventful 2024 for Lifecare following the Q3 report, which sported slightly higher revenues and lower costs than anticipate...
Following today's approval from the NFSA, Lifecare has received all necessary approvals to commence the LFC-SEN-002 study, which aims to eva...
Redeye has a positive view on Lifecare securing NOK42.
Redeye endorses Lifecare's disclosure of its laboratory in Mainz being considered ready for ISO 13485 audit, representing another concrete s...
Redeye views today's press release positively, stating that Lifecare has received development funding from Sanofi in accordance with the pro...
Redeye views the recent news from Lifecare, which confirms a minimum operational longevity of six months for Sencell, in a positive light.
Redeye initiates coverage of Lifecare, an innovative medtech company offering a next-generation continuous glucose monitor sensor.
